

Analysis of cause-specific atherothrombotic cardiovascular disease mortality in Mexico: 2011–2015

Erwin Chiquete^{1*}, Jorge Aldrete-Velasco², Sonia C. Juárez-Comboni³, David Solar-Cafaggi³, Salvador Durán-Coyote^{1,4}, Mercedes Scarlett Enriquez Ramos⁴, Benjamín Camacho-Silva⁴, Ana Ochoa-Guzmán¹, Carlos Cantú-Brito¹

¹Instituto Nacional de Ciencias Médicas y de la Nutrición Salvador Zubirán, Mexico

²Internal Medicine and Clinical Research. Paracelsus S.A. de C.V. Mexico City, Mexico

³Centro Médico ABC, Mexico City, Mexico

⁴Clinical Research and Biostatistics, Grupo ANLTYK, Mexico City, Mexico

Submitted: 26 December 2020; **Accepted:** 26 May 2022

Online publication: 29 May 2022

Arch Med Sci 2025; 21 (1): 67–74

DOI: <https://doi.org/10.5114/aoms/150436>

Copyright © 2022 Termedia & Banach

***Corresponding author:**

Erwin Chiquete
Instituto Nacional de
Ciencias Médicas
y de la Nutrición
Salvador Zubirán, Mexico
E-mail: erwin.chiquetea@incmnsz.mx

Abstract

Introduction: In Mexico, cardiovascular diseases (CVD) represent the most important cause of mortality, disability, and premature death. We aimed to analyze the mortality rate due to specific causes of atherothrombotic CVD, from 2011 to 2015.

Material and methods: We analyzed 3,105,975 death certificates issued between January 2011 and December 2015. The 10th version of the codes published by the International Classification of Diseases (ICD) was used to select CVD death records for ischemic heart disease, heart failure, cerebrovascular disease, and peripheral artery disease. Regional analyses from the different federal states were also performed to provide inferences on the economic regions of the country.

Results: We analyzed 594,370 (19.1%) death certificates with CVD as the basic cause of death occurring in Mexico during 2011–2015. Age-standardized CVD mortality showed a more stable pattern, from 96.7 per 100,000 people in 2011, to 111.7 per 100,000 in 2015. Cause-specific mortality rates increased more during the period for ischemic heart disease (63.8 vs. 74.8 per 100,000 people, in 2011 vs. 2015, respectively), as compared to heart failure (6.9 vs. 8.1 per 100,000 people), cerebrovascular disease (28.4 vs. 30.2 per 100,000 people), or peripheral artery disease (0.52 vs. 0.55 per 100,000 people). Overall, the survival age was significantly shorter in men (mean age at death 72.04 ±16.23 years) than in women (77.73 ±14.77). Ischemic heart disease and cerebrovascular disease showed the shortest survival. The number of deaths increased steadily among the older population, with the steepest increase for overall ischemic heart disease over time.

Conclusions: Atherothrombotic CVD mortality in Mexico increased during the study period, particularly at the expense of ischemic heart disease. Compared to their counterparts, survival age was shorter in men and in patients with ischemic heart disease and stroke.

Key words: cardiovascular disease, cerebrovascular disease, infarction, peripheral artery disease, stroke.

Introduction

Cardiovascular disease (CVD) is the leading cause of death in the world, with more than 17.9 million persons affected per year. It accounts

for approximately 30% of all deaths, out of which 80% occur in low- to middle-income countries [1–6]. It is estimated that by 2020, about 23.6 million people will die from CVD, alarmingly maintaining the first rank in mortality worldwide [4, 5]. CVD encompasses a group of disorders that affect the heart and blood vessels, including ischemic heart disease, cerebrovascular disease, peripheral artery disease (PAD), heart failure, and sudden death, among other atherothrombotic and non-atherothrombotic diseases. It is estimated that 92.1 million adults in the United States have at least one type of CVD. Among these patients, 46.7 million are people aged > 60 years [3, 4, 6].

In Mexico, CVD represents one of the most significant causes of disability and premature death, leading to a considerable increase in the cost of health care [5–7]. In 2008, CVD mortality accounted for more than 17% of all deaths in the country, and in 2012 approximately 109,000 people died from heart disease [7, 8]. Currently, CVD is the leading cause of death in the Mexican population. However, a small but constant decrease has been recently observed due to the implementation of programs such as the Infarction Code [6, 8]. Along with diabetes mellitus, the National Health System considers CVD as the main non-communicable health problem in the country [4]. We aimed to analyze the population mortality due to specific CVD causes of death during the period 2011–2015. Our hypothesis was that CVD mortality in Mexico is beginning to reach a plateau in annual population-adjusted mortality rates. These results are part of a comprehensive analysis that includes recent periods and non-communicable causes of death within the country.

Material and methods

In this descriptive observational study, a total database of 3,105,975 death certificates provided by SINAIS/DGIS was consulted during the period from January 2011 to December 2015. This database is made of all death certificates issued during the 2011–2015 period in the whole country (a total of 32 federal states) [9]. Briefly, in Mexico death certificates are registered locally in the informatics department of each healthcare institution, public ministry, and other legal entities of the respective municipality. These death records are consolidated by the SINAIS/DGIS in a comprehensive electronic database by using the global WHO format. A database is freely available for each year with the basic cause of death, excluding contributing causes and comorbidities [9]. Records of diseases associated to death due to atherothrombotic CVD were identified (as defined by the American Heart Association [AHA]), with the codes of the International Classification of Diseases tenth revision (ICD-10). We

selected and analyzed ICD-10 classification codes of ischemic heart disease (I25.0, I25.1, I25.2, I25.3, I25.4, I25.5, I25.6, I25.8, I25.9), heart failure (I50.0, I50.1, I50.9), cerebrovascular disease (I60.0, I60.1, I60.2, I60.3, I60.4, I60.5, I60.6, I60.7, I60.8, I60.9, I61.0, I61.1, I61.2, I61.3, I61.4, I61.5, I61.6, I61.8, I61.9, I63.0, I63.1, I63.2, I63.3, I63.4, I63.5, I63.6, I63.8, I63.9, I65.0, I65.1, I65.2, I65.3, I65.8, I65.9, I66.0, I66.1, I66.2, I66.3, I66.4, I66.8, I66.9, I67.0, I69.0, I69.1), and peripheral artery disease (I73.1, I73.9, I74.0, I74.1, I74.2, I74.3, I744, I74.5, I748, I74.9). These ICD-10 codes were used to put together a separate database to analyze established atherothrombotic CVD, excluding hypertension, heart arrhythmias, and thrombotic venous diseases. In this new electronic database, we identified the proportion of deaths associated with the specific causes of atherothrombotic CVD that were selected for the present analysis, taking into account the corresponding ICD-10 codes. Then, a database of death certificates was extracted (i.e., 132,148 deaths from atherothrombotic CVD as a basic cause of death), taking into account the basic causes of death reported by the Mexican Ministry of Health during the aforementioned period. These databases were analyzed without patient identification, social security numbers, hospital record numbers, or any personal contact details. A consent disclaimer was obtained for the present analysis of public raw data [9]. No risk exposures were derived from the present retrospective official database analysis.

Mortality rates were assessed by using the frequencies of ICD-10 usage (indicating that an individual died from CVD) and computed per 100,000 inhabitants of Mexico according to the population size of each year reported by the National Census of Population and Housing [10]. Age-standardized mortality rates were calculated using the World Health Organization (WHO) population model. For this calculation, the following data were used: Mexican national population at mid-year in the period of the prefixed analysis (2011–2015) and the number of deaths recorded in death certificates within each year of the period, for the selected specific causes of death and for CVD as the sum of the specific cases (ICD-10 codes). Demographic data are presented as relative frequencies. The Pearson χ^2 test (or Fisher's exact test, as appropriate) was used to compare the frequencies of qualitative nominal variables between two groups. All *p*-values for comparisons were two-tailed and results were considered statistically significant when *p* < 0.05. Economically active age groups were analyzed according to the definitions of the National Institute of Statistics, Geography and Informatics (INEGI) for this population sector [10].

Results

A total of 3,105,975 death certificates issued in Mexico were identified for the study period from January 2011 to December 2015. After applying the selection criteria for individual certificate records, a unified database was obtained with a total of 594,370 records corresponding to CVD as the basic cause of death. During 2011, a total of 107,227 death certificates accounted for CVD, which rose to 130,279 death certificates in 2015 (53.2% deaths corresponded to men in 2015) (Table I). The age-standardized mortality rate for CVD as the basic cause of death exhibited a trend that steadily increased during the period, from 92.7 per 100,000 in 2011, to 107.7 per 100,000 in 2015 (Table II).

The survival age was significantly shorter ($p < 0.001$) in men (mean age at death: 72.04 ±16.23 years) than in women (mean age at death: 77.73 ±14.77 years) (Figure 1 A). Such gender-related discrepancies in the age at death according to sex were maintained for ischemic heart disease (71.97 ±15.88 vs. 78.65 ±14.02 years, $p < 0.001$), heart failure (75.69 ±17.84 vs. 78.80 ±16.05 years, $p < 0.001$), cerebrovascular disease (71.71 ±16.72 vs. 75.55 ±15.71 years, $p < 0.001$), and peripheral artery disease (75.02 ±16.59 vs. 79.83 ±14.68 years,

$p < 0.001$). In general, ischemic heart disease and cerebrovascular disease had the shortest survival compared to heart failure or peripheral artery disease (Figure 1 B).

The crude number of deaths increased steadily among the population aged > 65 years, with a slope that was disproportional to the population growth in that particular age group (Figure 2). The increase was steeper for ischemic heart disease in the older population, while it was essentially stable for heart failure or peripheral artery disease (Figure 3).

The Mexican federal states contributed differently to CVD mortality during the period (Figure 4), without differences according to year of registry, age or sex.

Discussion

In this study we observed that CVD mortality shows a growing pattern, essentially at the expense of ischemic heart disease. Compared to women, men showed a younger age at death (i.e., survival age), which is an epidemiological concept that differs from “life expectancy,” which is a statistical measure of the mean time a human is expected to live, based on the year of birth.

Table I. Cardiovascular disease analyzed through death certificates during the period 2011–2015, according to sex. The numbers in parentheses represent the proportion that each year accounts for over the 5-year period

Number of deaths (% over the 5-year period)	Year of registry					Total
	2011	2012	2013	2014	2015	
Total cardiovascular disease						
Men	56693 (17.9)	60176 (19.0)	63944 (20.2)	65728 (20.8)	69647 (22.0)	316188 (100)
Women	50529 (18.2)	53315 (19.2)	56359 (20.3)	57312 (20.6)	60626 (21.8)	278141 (100)
Ischemic heart disease						
Men	38786 (17.6)	41279 (18.8)	44508 (20.2)	46176 (21.0)	49256 (22.4)	220005 (100)
Women	30479 (17.6)	32767 (18.9)	35067 (20.2)	36157 (20.9)	38882 (22.4)	173352 (100)
Heart failure						
Men	3097 (18.8)	3125 (19.0)	3395 (20.6)	3273 (19.9)	3593 (21.8)	16483 (100)
Women	3765 (19.7)	3866 (20.2)	3959 (20.7)	3723 (19.5)	3828 (20.0)	19141 (100)
Cerebrovascular disease						
Men	14557 (18.6)	15531 (19.8)	15763 (20.1)	16036 (20.5)	16511 (21.1)	78398 (100)
Women	15982 (19.0)	16371 (19.5)	16997 (20.2)	17128 (20.4)	17595 (20.9)	84073 (100)
Peripheral artery disease						
Men	253 (19.4)	241 (18.5)	278 (21.4)	243 (18.7)	287 (22.0)	1302 (100)
Women	303 (19.2)	311 (19.7)	336 (21.3)	304 (19.3)	321 (20.4)	1575 (100)

Table II. Number of deaths and age-standardized mortality rates per specific cardiovascular disease, 2011–2015

Parameter	Year of registry				
	2011	2012	2013	2014	2015
Ischemic heart disease					
Number of deaths	69268	74057	79586	82334	88144
Mortality rate per 100000	63.88	66.27	70.22	70.78	74.84
Heart failure					
Number of deaths	6862	6991	7354	6996	7421
Mortality rate per 100000	6.93	6.97	7.21	7.84	8.13
Cerebrovascular disease					
Number of deaths	30541	31905	32762	33165	34106
Mortality rate per 100000	28.40	29.26	29.67	29.70	30.18
Peripheral artery disease					
Number of deaths	556	553	614	547	608
Mortality rate per 100000	0.52	0.51	0.56	0.50	0.55
Overall cardiovascular disease					
Number of deaths	107227	113506	120316	123042	130279
Mortality rate per 100000	96.69	100.96	105.62	106.78	111.66




Figure 1. **A** – Kaplan-Meier plot showing the survival curves according to sex in the overall atherothrombotic cardiovascular disease death certificates database, 2011–2015. **B** – Kaplan-Meier plot showing survival curves according to specific causes of atherothrombotic cardiovascular diseases analyzed in this study, 2011–2015




Figure 2. Crude number of deaths due to total atherothrombotic cardiovascular disease, according to age and year of record. Numbers followed by “+” or “-” express the percentage increase or decrease, respectively, between the first and last year analyzed

Moreover, cause-specific analysis showed that the shortest survival was observed for ischemic heart disease and cerebrovascular disease, which are the causes of CVD death with the highest death tolls. These findings are relevant in general terms, since it has been estimated that approximately 80% of deaths due to CVD occur in low- to middle-income countries, affecting both sexes equally [1–6]. Moreover, the global CVD burden has increased over recent decades, in high- and low-to-middle-income nations. In Mexico, these diseases still represent a serious public health problem that entails a significant burden in terms of prevalence and medical care costs [1, 5, 6, 8–12].

Compared to previous reports about the speed of growth of atherothrombotic mortality in Mexico




Figure 3. Crude number of deaths due to specific causes of atherothrombotic cardiovascular disease, according to age and year of registry. Numbers followed by “+” or “-” express the percentage increase or decrease, respectively, between the first and last year analyzed




Figure 4. Number of deaths due to atherothrombotic cardiovascular disease from the different Mexican federal states, from 2011 to 2015. The numbers represent the contribution of each federal state to the entire atherothrombotic cardiovascular disease mortality rate in Mexico

[13], in the present analysis, we have potentially observed the historical inflection point of a progressive slowing of CVD mortality growth in Mexico. This phenomenon can be explained by a more widespread awareness among the Mexican population about the risk factors and clinical features of diseases that occur as a consequence of artery occlusions, as well as the implementation of programs such as the Infarction Code to control atherothrombotic diseases through the development of high-impact strategies aimed at raising awareness of the main causes of CVD morbidity and mortality [6, 8]. Nonetheless, in order to determine that such epidemiological pattern change is sustained, an extended analysis on recent years should be performed, and it is currently in preparation.

The economically active population is made up of people who provide labor for the production of goods and services. Among the most important causes of death within this sector of the population are diabetes mellitus and CVD, especially in people aged 45 to 64 years [9]. In the present study we observed that CVD deaths occurred in high numbers among the economically active population, an alarming finding considering the loss of the productive force of the nation. Furthermore, CVD mortality is higher in the most important federal states of Mexico, ranked by gross domestic product (GDP) and population size, such as Mexico City (a new federal state in Mexico), Jalisco, the State of Mexico, Veracruz, Puebla, and Nuevo León [10–12]. The explanation for this phenomenon could be related to the exposure to risk factors prevailing in large urban areas, although with the current methodology we cannot discard underdiagnosis of CVD entities in the small or underdeveloped regions of Mexico. This study presents key hypotheses currently being tested by our group and by other researchers.

Mexico is an upper middle-income country that has one of the highest prevalence rates for diabetes mellitus in the world [10, 13], in addition to the fact that glycemic control in people with this disease is often deficient and relates to frequent concomitant pathologies (e.g., CVD, dyslipidemia, hypertension, and end-stage renal impairment, among several others) that increase morbidity and mortality [14–16]. The WHO has suggested that there may be problems in reporting mortality associated with diabetes mellitus as the basic cause of death, because diabetes mellitus can in turn lead to CVD and other chronic micro- and macrovascular complications; therefore, when mutually exclusive basic causes of death are considered, CVD-related death in patients with diabetes mellitus may be assigned to the latter instead of atherothrombotic CVD [14, 17–21].

Our results are comparable to those recently observed in the Brazilian population [22], specifically with respect to the overall trends of CVD deaths. A remarkable difference versus the Brazilian report is that we limited the analysis of ICD-10 classification codes to specific atherothrombotic diagnoses, excluding the unspecific codes related to “diseases of the circulatory system” (ICD-10 codes I00–I99) and other unspecific codes to avoid the inclusion of garbage codes. This methodology, of course, might underestimate the CVD burden in Mexico, which will feature in a future analysis by our research team. Moreover, there is high potential for misclassification of the basic cause of death biased towards general diagnoses such as diabetes mellitus and hypertension, which represent very common comorbid conditions. This paper draws attention to what is considered a basic cause of death and how the mortality analyses are performed. Future studies need to address this issue. This fact can also be deduced from a comparison with CVD mortality in Argentina [23], which, globally, is higher than that reported in the present analysis [24]. Nevertheless, our study aimed to analyze the population mortality of specific atherothrombotic diseases, which may be important when discussing specific etiologies that conform the cardiovascular burden of disease.

The present study has limitations that must be addressed for an accurate interpretation of data. It is worth noting that this analysis addresses a relatively short period of time and that the last year is 2015; therefore, recent changes in epidemiological patterns cannot be detected. Another topic of discussion is that only the basic cause of death in the certificates was studied, as this is the only cause of death available in the public SINAIS/DGIS databases. Consequently, it is not known how many cases of people who died from CVD were related to other diagnoses, such as diabetes mellitus. It is also possible that heart failure has been either underdiagnosed or misclassified with other related causes of death, such as diabetes or hypertension [25]. Moreover, since a death certificate usually does not give an account of any previous atherothrombotic events, we were not able to analyze the possible influence of recurrent (versus first-ever) events explaining the differences in the causes of death analyzed. Another limitation is the lack of data on comorbidities and risk factors that may indirectly contribute to CVD deaths. Nevertheless, the results from this study are based on official death certificates pertaining to the Mexican public health system, which is the source of information for other estimations about disease burden [26].

In conclusion, although CVD mortality in Mexico is still increasing (particularly associated with

ischemic heart disease among the population aged > 65 years), compared with other reports we have observed a progressive slowing of CVD mortality growth. Moreover, compared to other clinical forms of CVD, patients with ischemic heart disease and cerebrovascular disease have the shortest survival. Male sex is also associated with a reduced survival age. These findings establish a basis for new research hypotheses aimed at better explaining the sex and regional disparities observed in our emerging economy.

Acknowledgments

The authors appreciate the collaboration of Dr. Carlos Fernandez Barros in the revision of the final manuscript.

Funding

This analysis received restricted funds from Boehringer-Ingelheim, Paracelsus, and ANLTYK. These companies did not propose the study, nor were they involved in data capture. Nonetheless, these companies participated in data analysis, drafting the manuscript and the decision to submit it for publication. Paracelsus provided editorial support, which was contracted and funded by Boehringer-Ingelheim.

Ethical approval

Not applicable.

Conflict of interest

Drs. Citlali Juárez-Comboni and David Solar-Cafaggi are also employees of Boehringer Ingelheim Mexico

References

- Rodríguez-Reyes H, Lara-Vaca S, Ochoa-Guzmán A, Chiquete E; ReMeFa Study Group. Obesity paradox and 12-month outcome in patients with atrial fibrillation. *Arch Med Res* 2021; 52: 233-9.
- Mazidi M, Katsiki N, Mikhailidis DP, Pella D, Banach M. Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. *Arch Med Sci* 2020; 16: 260-72.
- Benjamin E, Blaha M, Chiuve S, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation* 2017; 135: 146-603.
- Walicka M, Puzianowska-Kuznicka M, Chlebus M, et al. Relationship between age and in-hospital mortality during 15,345,025 non-surgical hospitalizations. *Arch Med Sci* 2021; 17: 40-6.
- Chiquete E, Sandoval-Rodríguez V, García-Grimshaw M, et al. Reliability of bystander recognition of clinical features in pre-hospital classification of acute cerebrovascular syndromes: preliminary findings. *Rev Invest Clin* 2020; 73. DOI: 10.24875/RIC.20000238.
- Rosas-Peralta M, Arizmendi-Urbe E, Borrayo-Sánchez G. [What do adults die in Mexico? Impact on the economic and social development of the nation. The global burden of cardiovascular disease]. *Rev Med Inst Mex Seguro Soc* 2017; 55: 98-103.
- Morales L, Flores Y, Leng M, et al. Risk factors for cardiovascular disease among Mexican-American adults in the United States and Mexico: a comparative study. *Salud Publica Mex* 2014; 56: 197-205.
- Rosas M, Borrayo G, Ramírez E, et al. Cardiovascular risk reduction: past, present and future in México. *Ann Clin Hypertens* 2018; 2: 038-047.
- General mortality databases, Mexico. Accessed July 20, 2020. (http://www.dgjs.salud.gob.mx/contenidos/basesdedatos/da_defunciones_gobmx.html).
- Censo de Población y Vivienda 2010. INEGI. Disponible en: <https://www.inegi.org.mx/programas/ccpv/2010/>
- Quezada AD, Lozada-Tequeanes AL. Time trends and sex differences in associations between socioeconomic status indicators and overweight-obesity in Mexico (2006-2012). *BMC Public Health* 2015; 15: 1244.
- Gutierrez JP, Agudelo-Botero M, Garcia-Saiso S, et al. Advances and challenges on the path toward the SDGs: subnational inequalities in Mexico, 1990-2017. *BMJ Glob Health* 2020; 5: e002382.
- Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. *Arch Med Res* 2015; 46: 328-38.
- Patsourakos NG, Kouvari M, Kotidis A, et al. The incidence of recurrent cardiovascular events among acute coronary syndrome patients treated with generic or original clopidogrel in relation to their sociodemographic and clinical characteristics. The Aegean study. *Arch Med Sci* 2020; 16: 1013-21.
- Mazidi M, Shekoohi N, Katsiki N, Banach M. Omega-6 fatty acids and the risk of cardiovascular disease: insights from a systematic review and meta-analysis of randomized controlled trials and a Mendelian randomization study. *Arch Med Sci* 2021; 18: 466-79.
- Alegre J, Herrington W, Lopez M, et al. Diabetes and cause-specific mortality in Mexico City. *N Engl J Med* 2016; 375: 1961-71.
- Einarson T, Acs A, Ludwig C, et al. The economic burden of cardiovascular disease in type 2 diabetes: a systematic review. *Value Health* 2018; 21: 881-90.
- Ramphul K, Ramphul Y, Sombans S, et al. Incidence and mortality rates of acute ischemic stroke in hospitalized patients in the United States. *Arch Med Sci Atheroscler Dis* 2021; 6: e132-4.
- AHA Statistical Update. Heart Disease and Stroke Statistics – 2018 Update. *Circulation* 2018; 137: 67-492.
- Maragkoudakis S, Marketou M, Katsi V, et al. The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. *Arch Med Sci Atheroscler Dis* 2021; 6: e176-81.
- Vintimilla R, Reyes M, Johnson L, Hall J, O'Bryant S. Cardiovascular risk factors in Mexico and the United States: a comparative cross-sectional study between the HABLE and MHAS participants. *Gac Med Mex* 2020; 156: 17-21.
- Malta DC, Teixeira R, Oliveira GMM, Ribeiro ALP. Cardiovascular disease mortality according to the Brazilian information system on mortality and the Global Burden of Disease Study estimates in Brazil, 2000-2017. *Arq Bras Cardiol* 2020; 115: 152-60.

23. Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. *BMC Public Health* 2010; 10: 627.
24. Orzechowski P, Piotrowicz R, Zareba W, et al. Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up – subanalysis of the TELEREhabilitation in Heart Failure Patients randomized clinical trial. *Arch Med Sci* 2021; 18: 293-306.
25. Alswat K. Type 2 diabetes control and complications and their relation to serum magnesium level. *Arch Med Sci* 2021; 18: 307-13.
26. Arroyo-Quiroz C, Barrientos-Gutierrez T, et al. Coronary heart disease mortality is decreasing in Argentina, and Colombia, but keeps increasing in Mexico: a time trend study. *BMC Public Health* 2020; 20: 162.